Management Strategies for Heart Failure with Preserved Ejection Fraction

The management of heart failure with preserved ejection fraction (HFpEF) is challenging and requires an accurate diagnosis. Although currently there is no convincing therapy that prolongs survival in patients with HFpEF, treatment of fluid retention and of comorbidities, such as hypertension, myocardial ischemia, and atrial fibrillation, may improve symptoms and quality of life. Future outcome trials testing the efficacy of promising new agents will have better characterization of patient phenotype to maximize the potential response to therapies. This article provides current management strategies available for HFpEF, gives an overview of previous trials that have failed to prove the benefit of therapies to improve outcomes, and highlights promising novel therapies.